We employed a low immunogenic murine melanoma cell line B16-F10 (B16), characterized by low MHC expression and resistance to ICB treatment and the immunogenic line B2905, which models highly mutated melanoma tumors (23, 24). This evidence concerns the gene HLA-C and melanoma.